Slingshot members are tracking this event:
Novartis (NVS) presented new Cosentyx (secukinumab) data from the prospective Phase III SCALP study
Slingshot Insights Explained
Feb 16, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Cosentyx, Phase 3 Study, Scalp, Secukinumab